Thorax, 01/09/2011 Review Article
Chang KC et al. – Intermittent tuberculosis treatment regimens have been developed to facilitate treatment supervision. Their efficacy has been substantiated by clinical trials and tuberculosis control programmes, notwithstanding the lack of head–to–head comparison between daily and intermittent regimens. Recently, there has been opposing evidence from observational studies, pharmacokinetic–pharmacodynamic studies that intermittent treatment increases the risk of relapse, treatment failure or acquired rifamycin resistance, especially among HIV–infected patients.
http://www.mdlinx.com/internal-medicine/newsl-article.cfm/3422417/ZZ880582144096849473028/?news_id=1604&newsdt=010911&subspec_id=1009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment